Swiss National Bank boosted its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 9.7% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 196,719 shares of the medical research company’s stock after purchasing an additional 17,400 shares during the period. Swiss National Bank owned about 0.17% of Exact Sciences Corporation worth $6,958,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in EXAS. BlackRock Inc. grew its position in Exact Sciences Corporation by 45,816.0% during the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock valued at $160,718,000 after purchasing an additional 6,789,478 shares in the last quarter. JPMorgan Chase & Co. grew its position in Exact Sciences Corporation by 98.1% during the first quarter. JPMorgan Chase & Co. now owns 4,985,657 shares of the medical research company’s stock valued at $117,761,000 after purchasing an additional 2,468,376 shares in the last quarter. Point72 Asset Management L.P. grew its position in Exact Sciences Corporation by 1,534.3% during the first quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock valued at $59,061,000 after purchasing an additional 2,347,476 shares in the last quarter. OppenheimerFunds Inc. grew its position in Exact Sciences Corporation by 66.8% during the first quarter. OppenheimerFunds Inc. now owns 2,502,398 shares of the medical research company’s stock valued at $59,107,000 after purchasing an additional 1,002,398 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Exact Sciences Corporation during the second quarter valued at approximately $29,450,000. 85.22% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently commented on EXAS. Canaccord Genuity reaffirmed a “buy” rating and set a $45.00 price objective on shares of Exact Sciences Corporation in a research report on Thursday, September 7th. BidaskClub raised shares of Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Leerink Swann set a $45.00 price objective on shares of Exact Sciences Corporation and gave the company a “buy” rating in a research report on Thursday, August 24th. Zacks Investment Research downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Vetr downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $38.66 price objective on the stock. in a research report on Thursday, August 3rd. Six analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Exact Sciences Corporation currently has an average rating of “Buy” and an average price target of $40.98.

In other Exact Sciences Corporation news, Director Thomas D. Carey purchased 2,500 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was bought at an average cost of $37.71 per share, with a total value of $94,275.00. Following the purchase, the director now directly owns 60,858 shares of the company’s stock, valued at $2,294,955.18. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP D Scott Coward sold 1,987 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the transaction, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The disclosure for this sale can be found here. Insiders have sold a total of 129,291 shares of company stock valued at $5,288,181 over the last ninety days. Company insiders own 4.00% of the company’s stock.

Shares of Exact Sciences Corporation (EXAS) opened at 42.75 on Friday. The firm has a 50-day moving average of $40.01 and a 200 day moving average of $32.49. The company’s market capitalization is $5.09 billion. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $43.50.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.10. The company had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. On average, analysts anticipate that Exact Sciences Corporation will post ($1.18) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Exact Sciences Corporation (EXAS) Shares Bought by Swiss National Bank” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/17/exact-sciences-corporation-exas-shares-bought-by-swiss-national-bank.html.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.